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RelapseAbstract Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease with
unknown origin. The disease causes a broad spectrum of signs and symptoms in a majority of body
organs. Due to several factors like damage to mucosal surfaces and defect in complement systems,
these patients are at a great risk of infections with opportunistic pathogens.
Aim of the work: To evaluate the nasal carriage of Staphylococcus aureus, rate of Methicillin-
resistant S. aureus (MRSA) and its correlation with relapse in lupus patients.
Patients and methods: In an analytical-descriptive study, 80 patients (65 female and 15 male)
with SLE attending the rheumatology clinics of Tabriz University of medical sciences were selected.
Nasal mucosa specimens of the patients were taken and incubated in appropriate culture environ-
ment. All of the patients were followed for 1 year and the relapse of the disease was evaluated.
Results: The mean age of the patients was 25.35 ± 5.87 years. The mean disease duration was
3.66 ± 2.27 years and the mean SLE disease activity index (SLEDAI) was 6.40 ± 2.84. Thirty-nine
out of 80 patients (48.75%) were positive for S. aureus in the nasal mucosa. Although no signiﬁcant
difference in SLEDAI was observed between the patients with nasal carriage of S. aureus and those
without, the two groups were signiﬁcantly different in the relapse and complement levels.
Conclusion: These results indicate that relapse of SLE in patients having S. aureus in their nasal
mucosa is higher than in patients without.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
Table 1 Systemic lupus erythematosus patients’ demographic
and clinical characteristics.
Number of patients (Female: Male) 80 (65:15)
mean ± SD
Age (years) 25.35 ± 5.78
Disease duration (years) 3.66 ± 2.27
SLEDAI 6.4 ± 2.84
Treatment regimens N (%)
HCQ+ P 53 (66.25)
HCQ+ P+ CYC 23 (28.75)
HCQ+ P+ Cyclosporine 4 (5)
HCQ, hydroxychloroquin; P, prednisolone; CYC, cyclophospha-
mide.
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Systemic lupus erythematosus (SLE) is an autoimmune disease
with a prevalence of 20–150 in 100,000 which mainly affects
young women in the range of 20–30 years [1,2]. Although the
exact etiology of the disease is not clearly understood, it is
thought to result from interplay of certain genetic factors,
environmental factors and the infections such as Epstein–Barr
virus (EBV) infection that is one of the suspected factors [3].
It has been shown that SLE patients are at high risk of dif-
ferent infections due to damage to mucosal surfaces, defect in
the immune system with lymphocyte dysfunction, complement
deﬁciency and spleen dysfunction as well as treatment with
immunosuppressive agents. These factors can also contribute
to disease relapse and hospitalizations of patients. The major
cause of death in the ﬁrst few years of illness is active disease
(e.g., cerebritis, nephritis, or cardiovascular disease) and/or
infection due to immunosuppression [4].
In some forms of vasculitis like Wegener’s granulomatosis,
the relationship between colonization of Staphylococcus aureus
in the nasal cavity and disease relapse has been studied [5,6].
Some other studies have indicated the colonization of these
bacteria in different parts of the body in patients with lupus.
Nasal cavity colonization of these bacteria may lead to pneu-
monia by the same organisms. To the best of our knowledge,
no study has been performed about the correlation between
disease relapse and the colonization of these bacteria in
patients with SLE. Previous studies have investigated the
organism in oral microﬂora [7,8] and intestine [9].
The aim of the present study is to evaluate S. aureus colo-
nization in SLE patients and their Methicillin-resistance and to
study its correlation with disease relapse.
2. Patients and methods
This analytical-descriptive study was performed in the internal
medicine department of Tabriz University of medical sciences,
Tabriz, Iran. We enrolled 80 patients with SLE referring to
Sina and Emam Reza hospitals and Sheikholraies clinic of
Tabriz in the years 2012–2013. SLE was diagnosed according
to the Systemic Lupus International Collaborating Clinics
(SLICC) Classiﬁcation Criteria [10].
The exclusion criteria were the anti-Staphylococcus therapy
in the past 1 month, and the immune deﬁciency related condi-
tions like diabetes, renal failure, IV drug abusing, cancers,
organ transplantation and human immunodeﬁciency (HIV)
infection. The ethics committee at the Tabriz University of
Medical Sciences reviewed and approved the present study,
in compliance with the Declaration of Helsinki. Informed con-
sent was obtained from all participants.
At the beginning of the study all of the patients were com-
pletely examined and a blood sample was taken for assessment
of the blood cell count, serum creatinine, anti-nuclear antibody
(ANA), anti-ds DNA and complement levels as well as a urine
sample for analysis.
The nasal sample was also obtained from the patients by a
microbiologist and was cultured for 48 h in Mannitol salt agar
environment after 16–20 h of incubation. Yellow colored colo-
nies were evaluated initially with Disc Diffusion Oxacillin
1 lm, if the samples were resistant; they were tested with E-test
for approving the MRSA. At the time of ﬂares nasal culturewas obtained again. The activity of SLE was evaluated using
the SELENA SLE disease activity index (SLEDAI). Patients
were followed up for 1 year and the ﬂare was diagnosed as fol-
lows [11]:
Mild/moderate ﬂare: a change in SLEDAI >3 points, or:
new/worse skin, stomatitis, serositis, arthritis, fever, or
increased prednisone <0.5 mg/kg/d, or added non-steroidal
anti-inﬂammatory drugs (NSAIDs)/hydroxychloroquine, or
>1.0 increase in a physician’s global assessment (0–3 scale).
Severe ﬂare: change in SLEDAI >12, or new/worse CNS-
SLE, vasculitis, nephritis, myositis, platelet count <60,000,
hemolytic anemia (Hb < 7 mg/dl), requiring doubling or
>0.5 mg/kg/d prednisone or hospitalization for SLE or new
immunosuppressive, and/or increased physician’s global
assessment to >2.5.
All the information from the patients was recorded conﬁ-
dential and the patients could leave the study at the time of
their decision.
Statistical evaluation was carried out with the SPSS 16.0
software (SPSS, Inc., Chicago, IL). Data obtained from the
study groups were compared by Student’s t-test and Mann–
Whitney U test. A p-value <0.05 was regarded as statistically
signiﬁcant. All the results are expressed as mean ± standard
deviation (SD).
3. Results
We studied 80 patients with SLE. Sixty-ﬁve patients (81.3%)
were females and 15 (18.7%) were males. Demographic and
clinical characteristics of patients are shown in Table 1.
Thirty-nine of the patients (48.72%) were carriers for
S. aureus upon the nasal mucosa culture in Mannitol salt agar
environment. From the 39 positive culture tests, 3 were resis-
tant in Disc Diffusion Oxacillin test for which the E-test was
done and all of them were sensitive.
Flare was seen at one year follow-up in 11 patients
(13.75%). All of the ﬂares were mild/moderate except for
one severe ﬂare in the S. aureus carriage group.
Both carriers and non-carriers of S. aureus did not differ
signiﬁcantly from each other regarding the SLEDAI, age and
sex (Table 2). Hypocomplementemia was signiﬁcantly more
frequent in carriers (p= 0.012).
There was no signiﬁcant association between the presence
of renal involvement in carriers and non-carriers of S. aureus
(p= 0.012) and recurrence had a signiﬁcantly higher rate
Table 2 Characteristics of S. aureus carrier and non-carrier
SLE patients.
Parameters Carriers of
S. aureus
(n= 39)
Non Carriers
of S. aureus
(n= 41)
p value
Sex N (%)
Female 32(18.1) 33(80.5) NS
Male 7(17.9) 8(19.5) NS
Hypocomplementemia 31(79.5) 12(29.3) 0.012
SLEDAI 5.4 6.4 NS
Flare during study 8 (20.5) 3 (7.3) 0.024
Mean time to ﬂare
from beginning of
study (months)
2.95 ± 1.46 3.12 ± 1.32 0.043
Types of ﬂare
Mild/Moderate 7 3 NS
Severe 1 0 NS
NS, non signiﬁcant.
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time to recurrence in patients carrying S. aureus was signiﬁ-
cantly shorter than non-carrier patients (p= 0.043). The mean
SLEDAI in patients with recurrence was 5.45 ± 2.34 and in
patients without recurrence was 4.76 ± 2.56, which were not
signiﬁcantly different from each other (p= 0.221).
The correlation between the disease duration and S. aureus
carrying was found to be signiﬁcant, so the carrier rate
increased with the increase in duration of the disease
(R= 0.566).
Ten (4.24%) of non-carriers of S. aureus and 17 (6.43%)
patients of carriers were on immunosuppressive drugs and
there was no signiﬁcant relation between immunosuppressive
therapy and S. aureus carrying (p= 0.57).
4. Discussion
Systemic lupus erythematosus (SLE) is an autoimmune multi-
systemic disease producing autoantibodies against different
parts of the body. Infections are a common complication
and a major cause of death in all stages of SLE. Although
infectious agents are known to trigger lupus disease expression
and activity, the risk of different infections also is high in such
patients [12]. Relapse of the disease is one of the major prob-
lems in the course of this illness.
Although etiologies of these relapses are not known, it
seems that infections have a signiﬁcant role in this matter.
Chen et al. recently reported that in Taiwanese patients
with SLE, S. aureus was the most common Gram-positive bac-
teremia and nontyphoidal Salmonella and Escherichia coli
were the most common Gram-negative pathogens isolated bac-
teria [13]. Gulneva et al. showed that in the intestine of patients
with SLE, there was a signiﬁcant increase of Staphylococcus
and opportunistic Enterobacteriaceae detection rate [9].
The rate of carrying S. aureus in patients with SLE and the
resistance for Methicillin and its relationship with the relapse
of the disease were the main objectives of present study. Most
of the current patients were categorized as having mild and
moderate disease activity and only a small number of patients
had a severe disease.In the current study, the S. aureus rate of carrying was
48.72% which is more compared to the results of another
study [14]. This study showed for the ﬁrst time in an Iranian
population that no MRSA cases were seen in patients with
lupus and this is important in selection of the right antibiotic.
The relapse of the disease was signiﬁcantly higher in carriers
while the disease activity, renal involvement, age and gender
were not different. It seems that S. aureus carrying can show
a higher rate of disease relapse. One major weakness is the
small number of patients enrolled in the present study.
The reduction of the complements associated with the
chance of carrying may reﬂect the role of complement system
against the infections in patients of this study. We found that
the longer the disease duration, the more the occurrence of car-
rying. The reason may be the decrease in complement levels,
increase in hospitalization and the increase of colonization of
S. aureus in such patients.
The immunosuppressive medications used in SLE of this
study further contribute to susceptibility to infections. A pro-
spective study of 110 lupus patients has shown that hypocom-
plementemia and a daily dose of prednisone greater than
20 mg for at least a month plus use of cyclophosphamide were
signiﬁcantly associated with infection [15]. In this study
although 10 patients from 41 patients of non carrying and 17
patients from 39 patients of carrying S. aureus were on treat-
ment with cyclophosphamide or cyclosporine, the differences
between them were not statistically signiﬁcant.
To our knowledge, this is the ﬁrst study to report the rela-
tion of carrying S. aureus and relapse in patients with SLE in
Iranian patients. Based on the results of our study, as well as
data from other related studies, the rate of carriers of S. aureus
in patients with SLE is higher compared with healthy subjects
and the relapse of the disease is higher in such patients.
In conclusion, in patients harboring S. aureus, recurrence
was signiﬁcantly more common, whereas disease activity, renal
involvement and age and gender differences were not signiﬁ-
cant. It can be concluded that the elimination of S. aureus from
nasal cavity can reduce recurrence. But to establish this theory
we need to conduct another study for the comparison of
relapse with or without elimination of S. aureus in patients
with lupus.Conﬂict of interest
None.
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